July 25, 2014



The cost of research and development in the drug industry — the cost of clinical trials in particular — is rising significantly. Still more than 95% of the experimental medicines that are studied in humans fail to be both effective and safe.

The good news is, soon it will be possible to test drugs directly on 3D printed functional living tissues.

Bio 3D printing company Organovo announced that it has entered into an agreement with Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson, to evaluate the use of 3D bio-printed tissue in a drug discovery setting, according to a document filed with the SEC Thursday.

Further financial terms are not disclosed. Janssen will work with Organovo to develop printable tissue for drug research. 3D printer could create living human tissues that more closely reproduce in vivo human tissues. These tissue models will give researchers a more accurate view of how drugs will behave in human beings.

This agreement is outside of the Company's work in 3D liver tissue for toxicity testing. In January this year, Organovo also announced they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists print more reliable eye tissue for bringing safer, more effective treatments to patients on a faster timeline.



Shares of Organovo (NYSEMKT:ONVO) are up 5% on robust volume in response this news.









Posted in 3D Printer Applications

Maybe you also like:











